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INTRODUCTION
Pressurized metered-dose inhalers (pMDIs) are the most widely
used devices for delivery of aerosol medications due to their
effectiveness and relative simplicity of use.1 However, an impor-
tant weakness of pMDIs is their propensity to be used sub-
optimally or incorrectly,2 a problem that has been recognized since
their inception and that is unfortunately still present today.3 In a
survey conducted among persons referred by family physicians,
internists, surgeons, and pulmonologists for routine spirometry,
only 10.8% of the subjects correctly performed all the maneuvers
recommended for self-administration and 24.7% failed to perform
more than half the maneuvers adequately.4 A review of 2123
patients with asthma by the National Services for Health
Improvement found that, without training, 86% failed to properly
use their inhaler.5 Even with inhaler training, some people will
revert to bad technique, and some will not benefit from training.6
One of the most common errors associated with pMDIs is the lack
of coordination between inhaler actuation and inhalation.2 Co-
ordination between inhalation and generation of the aerosol, so
that the inhaler should be activated just after onset of inspiration,
is crucial to increase drug deposition in the lung during pMDI
use.7 In the CRITIKAL study, poor coordination between inhaler
activation and inhalation led to a greater likelihood of uncon-
trolled asthma symptoms and a higher rate of exacerbations.8
Spacers and valved holding chambers (VHCs) are medical
devices, made of either polycarbonate plastics or metal, that
interface with the pMDI. They are shaped like a tube with
openings at both ends: one opening is the mouthpiece that is
placed into the mouth (or a facemask fitting the spacer with a
tight seal) and the other opening is where the pMDI is inserted.9-11
In this way, they provide additional space for the aerosol plume
to develop.9-11 In fact, with either a spacer or a VHC, the aerosol
flows from the pMDI into the chamber, thus allowing deceler-
ation of the aerosol plume and, in the case of VHCs, trap the
aerosol cloud until the patient inhales from the chamber rather
than directly from the pMDI.9-11 This greatly reduces oropha-
ryngeal drug deposition via retention of large aerosol particles
within the holding chamber, thus reducing the potential for
corticosteroid-related local side effects (ie, candidiasis and
dysphonia) and systemic absorption.9-11 Although the terms
“spacer” and “VHC” are frequently used interchangeably, the
former is a generic term for any open tube, sometimes made
from household items such as toilet paper rolls or plastic sodabottles,12,13 placed on the mouthpiece of the pMDI to extend its
distance from the patient’s mouth.9-11 However, a VHC is a
spacer that is manufactured with a 1-way, low-resistance valve to
regulate inspiratory flow and prevent exhalation into the device.9-11
The newer VHCs such as the AerochamberFlow-Vu (Trudell
Medical International, London, Ontario, Canada), the Opti-
Chamber Diamond (Philips Respironics, Guildford, Surrey,
UK), or the InspiraChamber (Lupin Pharmaceuticals, Pune,
Maharashtra, India) have an alert whistle to provide feedback on
correct inspiratory flow.14 The VHCs are generally preferable to
simple spacers because the latter, because of the lack of a 1-way
valve, are susceptible to dispersal of the aerosol within due to
uncoordinated exhalation into the chamber. In addition, VHCs
substantially lessen the need of inhaler actuation-inhalation
coordination, which is problematic for both adults1,2 and
children.15 As a result, VHCs may increase pulmonary deposi-
tion of drug suspensions16 and, compared with the pMDI alone,
may improve clinical outcomes including airway hyper-
responsiveness,17 lung function,18-20 and asthma control,21 with
a reduction in the requirement for oral corticosteroids.22
Accordingly, the use of VHCs is firmly recommended in inter-
national guidelines on the management of asthma23-25 and
chronic obstructive pulmonary disease26 (Table I), particularly in
patients prone to pMDI handling errors.27 Although patients
who have correct technique with pMDIs may not derive any
benefit from the use of VHCs,27 the latter reduce oropharyngeal
deposition of large aerosol particles emitted from a pMDI, even
with “perfect” technique.28
Although the potential benefits of spacers/VHCs are clear,
there is less consensus as to whether there are any meaningful
differences between different devices. There is substantial,
occasionally contradictory, literature detailing the relative per-
formance of a large number of different spacers or VHCs.29 It is
well established from in vitro studies that a specific VHC may
perform differently with different drugs30-32 or a specific drug
may perform differently in terms of emitted fine particle mass if
inhaled through different VHCs.33 Thus, substitution of one
type of spacer or VHC with another may have both safety and
clinical implications unless otherwise proven as equivalent
through in vitro and/or in vivo studies. Hatley et al34 found that
the aerodynamic particle size distribution of albuterol aerosols
obtained by 2 antistatic VHCs was similar but significantly
different from that obtained by using a conventional VHC.
Recently, D’Vaz et al35 reported no difference in the broncho-
dilator response, as assessed by FEV1 changes, to salbutamol
inhaled through different spacers in children with asthma.35
Accordingly, radiolabeled aerosol studies found equivalent lung
deposition of aerosol using different spacers.36 However, detec-
tion of differences in the bronchodilator response to an agent
delivered by different devices may be difficult due to the
potentially confounding effects related to the patient inhalation
technique, as well as due to the variability in the levels of airway
narrowing, especially when such variability is not adequately
accounted for in patient selection.18,19 In addition, even low
doses of bronchodilators delivered by virtually any inhalation
device may produce near-maximal bronchodilator responses
falling on the flat part of the dose-response curve.18,19,37
Although some studies failed to show significant differences in
lung deposition between different spacers/VHCs,36 others found
that large-volume (750 mL) resulted in greater whole lung
deposition compared with smaller devices.38 Differences in the
TABLE I. Guidelines recommending spacer or VHCs
Institution Year Recommendation(s)
American Association of
Respiratory Care
2007 A spacer/VHC should be used with an MDI; a spacer/VHC with facemask is appropriate for
patients (usually < 3 y) unable to use a mouthpiece.
American College of Chest
Physicians/American College
of Allergy, Asthma &
Immunology
2005 For patients who have trouble coordinating inhalation with device actuation, the use of a spacer
(with a valve) may obviate this difficulty; the use of spacers is mandatory for infants and
young children.
British Thoracic Society/Scottish
Intercollegiate Guidelines
Network
2012 Children and adults with mild and moderate exacerbations of asthma should be treated by
bronchodilators given from a pMDI þ spacer/VHC, with doses titrated according to clinical
response; in children aged 0-5 y, pMDI þ spacer are the preferred method of delivery of b2
agonists or inhaled steroids; the spacer should be compatible with the pMDI being used.
Canadian Pediatric Asthma
Consensus Guidelines
2005 The use of a VHC with pMDI is strongly recommended for children.
Canadian Thoracic Society 2010 The addition of a VHC with mouthpiece is helpful in overcoming poor hand-mouth
coordination and reducing side effects, with increased drug delivery and lung deposition;
VHCs with facemask attachments are useful for the elderly, who can use 4-6 tidal breaths
for each actuation of the medicine.
Global Initiative for Asthma 2017 pMDI þ dedicated spacer/VHC with facemask is the preferred delivery system for children
aged 4 y and younger; pMDI þ dedicated spacer/VHC with mouthpiece is the preferred
delivery system for children aged between 4 and 6 y.
Global Initiative for Chronic
Obstructive Lung Disease
2014 For the MDI, the addition of a large- or small-volume spacer often overcomes coordination
problems, and improves lower airway deposition and clinical benefit.
International Primary Care
Respiratory Group
2006 The preferred device for administering inhaled asthma medication for infants and young
children is a pMDI with a spacer and face mask; as the child’s ability to co-operate improves
(often around the age of 4-6 y), a spacer with a mouthpiece can be used rather than a
facemask.
National Heart, Lung, and Blood
Institute
2007 All patients taking inhaled steroids should use a pacer/VHC; patients younger than 5 y should
use a spacer/VHC with facemask for inhaled steroids.
Dutch College of General
Practitioners (NHG) guidelines
asthma and COPD
2014 Children: pMDIs should always be used in combination with a spacer/VHC.
Adults: pMDIs should always be used in combination with a spacer/VHC, unless the patient
can use a pMDI adequately.
National Institute for Clinical
Excellence (UK)
2010 Spacer/VHC recommended with a facemask where necessary for both corticosteroids and
bronchodilators (children younger than 5 y); a pMDI used with an appropriate spacer/VHC
is first choice for corticosteroids (children aged 5-15 y); for patients with chronic obstructive
pulmonary disease, pMDI alone is rarely suitable for use with the elderly; the spacer should
be compatible with the patient’s pMDI.
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dictory results.
Dissanayake et al39 set out to address the impact of spacer
design on drug delivery performance and look at potential im-
plications for clinical use. Four similarly sized chambers were
compared “out of the box” in terms of statistical equivalence with
the most widely prescribed, nonconducting VHC, Aerochamber
Plus chamber (Trudell Medical International) with respect to
retention of drug particles within the device and the aerodynamic
particle size distribution of the drug particles delivered. The au-
thors found that only the Aerochamber Flow-Vu chamber
demonstrated an equivalent profile of dose retention and delivery
versus the reference chamber. The Compact Space Chamber Plus
(Medical Developments, Victoria, Australia), the OptiChamber
Diamond, and InspiraChamber devices all retained approximately
twice as much drug, delivering around half the dose and showing
nonequivalent performance compared with the Aerochamber
Flow-Vu chamber and the reference chamber (pretreated Aero-
chamberPlus chamber). Thus, the performance of VHCs that
resemble one another in terms of appearances and dimensions may
differ markedly, implying that VHCs should not automatically be
considered interchangeable.39 Although equivalent performancebetween different VHCs has been demonstrated,34 a recent
in vitro study40 and a literature review14 provide further support
for the results found by Dissanayake et al.39 In considering the
important attributes of such delivery devices, the review notes a
shift in emphasis from chamber size and shape to other aspects,
such as consistency of drug delivery, static charge reduction, valve
performance, and factors optimizing facemask effectiveness, such
as flexibility and seal.14 Because differences exist between different
spacers or different VHCs, which in some cases are sufficiently
large that meaningful and overt clinical differences would be
anticipated as a result, each pMDI spacer/VHC combination
should be treated as a unique inhaled medication delivery sys-
tem.29 In this connection, the European Medicines Agency
guidance recommends that the development and registration
process for drug products delivered by pMDIs include testing and
supporting in vitro and in vivo data of the pMDI when used with
at least 1 named spacer/VHC.41 In addition, the European
Medicines Agency guidance states that patients with asthma with
well-controlled disease by inhaled medications delivered through
pMDIs plus spacer/VHC should always use the same type of
spacer/VHC and not switch to a different spacer/VHC that may
deliver different amounts of drugs.41
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(Summary of Product Characteristics and Patient Information
Leaflet) specifically notes that the VHC to be used should be
based on the device used in the product development/registra-
tion studies. In case of a spacer/VHC substitution, appropriate
equivalency data for the alternative device must be presented.41
Surprisingly, at variance with European Medicines Agency,
other regulatory authorities, such as for instance the US Food
and Drug Administration, do not require data for a specific
named spacer to support pMDI approval. However, in a draft
Food and Drug Administration Chemistry, Materials and
Controls Industry guidance for orally inhaled products issued in
1998 by the Center for Drug Evaluation and Research, there
is recognition that clinical efficacy assessment of
pMDI-delivered aerosols requires consideration of the presence
of a spacer/VHC.42
CONCLUSIONS
There is published evidence that the union of a particular
pMDI and a given spacer/VHC is considered a specific inhaled
medication delivery system. Therefore, we recommend physi-
cians to focus on selecting the most appropriate spacer/VHC for
the patient and their pMDI(s), given the weight of clinical evi-
dence available. Although the noninterchangeability of VHCs is
recognized,14,34,40 we also recommend clinicians to monitor for
any changes in disease control if the patient’s VHC was switched.
Furthermore, we believe that pharmacists need to appreciate that
spacers/VHCs may deliver different amounts of drug from the
pMDI and therefore substitution of a different device from that
prescribed by the physician may have an impact on the patient.
Finally, regulatory authorities need to be aware of the risks
inherent in the current approval process of spacer VHCs through
CE mark registration and look for improvements to, at the very
least, restrict the ability of devices with serious design/quality
flaws to be approved and used by patients.
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